Patrys Limited develops natural human antibody-based therapeutic products for the treatment of lung, pancreatic, gastric, and colon cancers. The company's lead products include PAT-SM6 and PAT-LM1, which are anti-cancer natural human antibodies for the treatment of multiple cancers; and PAT-SC1 that completed Phase I/IIa trial for the treatment of gastric cancer. It also develops various human antibody discovery programs in infectious diseases for which treatments are needed, including programs in Hepatitis C, malaria, and Staphylococcus A. In addition, the company is exploring opportunities to use its technologies in other disease areas, such as cardiovascular, autoimmune, and central nervous system disorders. Patrys Limited has collaborations with AstraZeneca/Cambridge Antibody Technology and Debiopharm S.A. It operates in Australia, Germany, and the United States. The company was founded in 2006 and is headquartered in Melbourne, Australia.

Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA.

Crealta Pharmaceuticals LLC operates as a specialty pharmaceutical company. The firm pursuing the acquisition of specialty pharmaceutical products with a focus on select therapeutic areas. The company was founded in August 2013 and is headquartered in Lake Forest, IL.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Board of Trustees of Michigan State University, part of Michigan State University, is an American company that trusts Except Educational Religious.

Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development. Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms. Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Dow Pharmaceutical Sciences, Inc. develops and distributes topical drug products. The firm provides product development services including formulation and regulatory consulting, formulation optimization utilizing state-of-the-art in vitro permeation models, full analytical support, cGMP clinical manufacturing and clinical labeling. The company was founded by Gordon J. Dow in 1977 and is headquartered in Petaluma, CA.

Provides biotechnology and research services and develops cell therapy technology

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Getty Images, Inc. creates and distributes visual and digital media contents through online. Its products include Getty images API, media manager, image.net, iStock and Photos.com. The firm offers rights and clearances, image collections, plugins and extensions, premium access and custom solutions. The company was founded by Mark Harris Getty and Jonathan David Klein in March 1995 and is headquartered in Seattle, WA.

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

Oncolix, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of medical therapies for the treatment of various cancers including ovarian, breast, uterine, and prostate. Its brand Prolanta is a drug designed to block the effect of human prolactin in cancers, either as a stand-alone therapy or in combination with other drugs, by blocking the effect of human prolactin. The company was founded on June 2013 and is headquartered in Houston, TX.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.